Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study

被引：0

作者：

Ciruelos, E. M. ^{[1
]}

Hamilton, E. P. ^{[2
]}

Kim, S-B. ^{[3
]}

Im, Y-H. ^{[4
,5
]}

Solis, E. Segui ^{[6
]}

Saenz, J. A. Garcia ^{[7
]}

Di Sanzo, A. ^{[8
]}

Lizarbe, M. Dominguez ^{[9
]}

Wasserman, T. ^{[10
]}

Theall, K. P. ^{[11
]}

Ibrahim, N. K. ^{[12
]}

机构：

[1] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Sungkyunkwan Univ, Med Dept Hematol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[5] Sungkyunkwan Univ, Med Oncol Div, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[6] Hosp Clin August Pi Sunyer Biomed Res Inst IDIBAP, Dept Med Oncol, Barcelona, Spain

[7] Inst Invest Sanitaria Hosp Clinico San Carlos, Dept Med Oncol, Madrid, Spain

[8] Biostatist & Data Management Dept, Menarini Grp, Florence, Italy

[9] Menarini Grp, Clin Res Dept, Florence, Italy

[10] Global Med Affairs Dept, Menarini Grp, Florence, Italy

[11] Global Product Dev Dept, Menarini Grp, New York, NY USA

[12] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.312

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

364P

引用

页码：S370 / S370

页数：1

共 50 条

[31] Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)
Hamilton, E.
Vidula, N.
Ma, C.
LoRusso, P.
Bagley, R. G.
Yu, Z.
Annett, M.
Weitzman, A.
Conlan, M. G.
Weise, A.
ANNALS OF ONCOLOGY, 2019, 30
[32] Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2-EBC)
Bardia, Aditya
Schmid, Peter
Harbeck, Nadia
Rimawi, Mothaffar F.
Hurvitz, Sara A.
Loi, Sherene
Saji, Shigehira
Jung, Kyung Hae
Werutsky, Gustavo
Stroyakovskii, Daniil
Lopez-Valverde, Vanesa
Tesarowski, David
Ye, Chenglin
Davis, Michael
Crnjevic, Tanja Badovinac
Perez-Moreno, Pablo Diego
Geyer, Charles E., Jr.
CANCER RESEARCH, 2022, 82 (04)
[33] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
Mayer, Erica L.
Tolaney, Sara M.
Brufsky, Adam
Gradishar, William John
Jhaveri, Komal L.
Martin, Miguel
Moscetti, Luca
Schneeweiss, Andreas
Vidal, Gregory A.
Cortazar, Patricia
Feldman, Merilin
Day, Bann-mo
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Bardia, Aditya
Kaklamani, Virginia
Wilks, Sharon
Weise, Amy
Richards, Donald
Harb, Wael
Osborne, Cynthia
Wesolowski, Robert
Karuturi, Meghan
Conkling, Paul
Bagley, Rebecca G.
Wang, Yamei
Conlan, Maureen G.
Kabos, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (12) : 1360 - +
[35] lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2-eBC)
Geyer, Charles
Bardia, Aditya
Harbeck, Nadia
Rimawi, Mothaffar F.
Hurvitz, Sara A.
Martin, Miguel
Loi, Sherene
Saji, Shigehira
Jung, Kyung Hae
Werutsky, Gustavo
Stroyakovskiy, Daniil
Lopez-Valverde, Vanesa
Davis, Michael
Crnjevic, Tanja Badovinac
Perez-Moreno, Pablo Diego
Schmid, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Dickler, Maura N.
Saura, Cristina
Richards, Donald A.
Krop, Ian E.
Cervantes, Andres
Bedard, Philippe L.
Patel, Manish R.
Pusztai, Lajos
Oliveira, Mafalda
Cardenas, Alison K.
Cui, Na
Wilson, Timothy R.
Stout, Thomas J.
Wei, Michael C.
Hsu, Jerry Y.
Baselga, Jose
CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387
[37] Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)
Skriver, Signe Korsgaard
Laenkholm, Anne-Vibeke
Rasmussen, Birgitte Bruun
Handler, Juergen
Grundtmann, Bo
Tvedskov, Tove Filtenborg
Christiansen, Peer
Knoop, Ann S.
Jensen, Maj-Britt
Ejlertsen, Bent
ACTA ONCOLOGICA, 2018, 57 (01) : 31 - 37
[38] Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).
Jhaveri, Komal L.
Boni, Valentina
Sohn, Joohyuk
Villanueva-Vasquez, Rafael
Bardia, Aditya
Schmid, Peter
Lim, Elgene
Patel, Jaymin M.
Alejandro Perez-Fidalgo, Jose
Loi, Sherene
Im, Seock-Ah
Kshirsagar, Smita
Gates, Mary R.
Bond, John
Eng-Wong, Jennifer
Chang, Ching-Wei
Turner, Nicholas C.
Lopez Miranda, Elena
Garcia-Estevez, Laura
Bellet, Meritxell
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2-aBC) who had rapid progression (RP) in acelERA BC
Martin Jimenez, M.
Hilz, S.
Collier, A.
Chibly, A.
Sohn, J.
Bardia, A.
Lim, E.
Mac Gregor, M. Chavez
Martinalbo, J.
Perez-Moreno, P. D.
Moore, H. M.
ANNALS OF ONCOLOGY, 2023, 34 : S356 - S357
[40] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
Rugo, H.
Tolaney, S.
Dickler, M.
Kabos, P.
Ho, C-L
Wildiers, H.
Jerusalem, G.
Ales-Martinez, J. E.
Hossain, A.
Johnston, E.
Gianni, L.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →